FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2076479050> ?p ?o ?g. }

• W2076479050 endingPage "1996" @default.
• W2076479050 startingPage "1982" @default.
• W2076479050 abstract "The treatment of some cancer patients has shifted from traditional, non-specific cytotoxic chemotherapy to chronic treatment with molecular targeted therapies. Imatinib mesylate, a selective inhibitor of tyrosine kinases (TKIs) is the most prominent example of this new era and has opened the way to the development of several additional TKIs, including sunitinib, nilotinib, dasatinib, sorafenib and lapatinib, in the treatment of various hematological malignancies and solid tumors. All these agents are characterized by an important inter-individual pharmacokinetic variability, are at risk for drug interactions, and are not devoid of toxicity. Additionally, they are administered for prolonged periods, anticipating the careful monitoring of their plasma exposure via Therapeutic Drug Monitoring (TDM) to be an important component of patients’ follow-up. We have developed a liquid chromatography–tandem mass spectrometry method (LC–MS/MS) requiring 100 μL of plasma for the simultaneous determination of the six major TKIs currently in use. Plasma is purified by protein precipitation and the supernatant is diluted in ammonium formate 20 mM (pH 4.0) 1:2. Reverse-phase chromatographic separation of TKIs is obtained using a gradient elution of 20 mM ammonium formate pH 2.2 and acetonitrile containing 1% formic acid, followed by rinsing and re-equilibration to the initial solvent composition up to 20 min. Analyte quantification, using matrix-matched calibration samples, is performed by electro-spray ionization–triple quadrupole mass spectrometry by selected reaction monitoring detection using the positive mode. The method was validated according to FDA recommendations, including assessment of extraction yield, matrix effects variability (<9.6%), overall process efficiency (87.1–104.2%), as well as TKIs short- and long-term stability in plasma. The method is precise (inter-day CV%: 1.3–9.4%), accurate (−9.2 to +9.9%) and sensitive (lower limits of quantification comprised between 1 and 10 ng/mL). This is the first broad-range LC–MS/MS assay covering the major currently in-use TKIs. It is an improvement over previous methods in terms of convenience (a single extraction procedure for six major TKIs, reducing significantly the analytical time), sensitivity, selectivity and throughput. It may contribute to filling the current knowledge gaps in the pharmacokinetics/pharmacodynamics relationships of the latest TKIs developed after imatinib and better define their therapeutic ranges in different patient populations in order to evaluate whether a systematic TDM-guided dose adjustment of these anticancer drugs could contribute to minimize the risk of major adverse reactions and to increase the probability of efficient, long lasting, therapeutic response." @default.
• W2076479050 created "2016-06-24" @default.
• W2076479050 creator A5014858344 @default.
• W2076479050 creator A5017226545 @default.
• W2076479050 creator A5019730399 @default.
• W2076479050 creator A5031165822 @default.
• W2076479050 creator A5034931288 @default.
• W2076479050 creator A5039207289 @default.
• W2076479050 creator A5050148338 @default.
• W2076479050 creator A5057871927 @default.
• W2076479050 creator A5058631792 @default.
• W2076479050 creator A5089255306 @default.
• W2076479050 date "2009-07-01" @default.
• W2076479050 modified "2023-10-11" @default.
• W2076479050 title "Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry" @default.
• W2076479050 cites W139116624 @default.
• W2076479050 cites W1515542254 @default.
• W2076479050 cites W1974028635 @default.
• W2076479050 cites W1975391266 @default.
• W2076479050 cites W1977706673 @default.
• W2076479050 cites W1977961949 @default.
• W2076479050 cites W1978821257 @default.
• W2076479050 cites W1988586881 @default.
• W2076479050 cites W1991417422 @default.
• W2076479050 cites W1992527646 @default.
• W2076479050 cites W1993205583 @default.
• W2076479050 cites W1997567636 @default.
• W2076479050 cites W1998182640 @default.
• W2076479050 cites W2015015957 @default.
• W2076479050 cites W2022263713 @default.
• W2076479050 cites W2030353836 @default.
• W2076479050 cites W2034074778 @default.
• W2076479050 cites W2037535290 @default.
• W2076479050 cites W2038669670 @default.
• W2076479050 cites W2039698853 @default.
• W2076479050 cites W2041196278 @default.
• W2076479050 cites W2045194073 @default.
• W2076479050 cites W2050226999 @default.
• W2076479050 cites W2055515709 @default.
• W2076479050 cites W2058677025 @default.
• W2076479050 cites W2061860992 @default.
• W2076479050 cites W2068639674 @default.
• W2076479050 cites W2075386470 @default.
• W2076479050 cites W2081637209 @default.
• W2076479050 cites W2082732399 @default.
• W2076479050 cites W2084186145 @default.
• W2076479050 cites W2091137497 @default.
• W2076479050 cites W2091517424 @default.
• W2076479050 cites W2095406737 @default.
• W2076479050 cites W2095872611 @default.
• W2076479050 cites W2110444464 @default.
• W2076479050 cites W2115817675 @default.
• W2076479050 cites W2116177733 @default.
• W2076479050 cites W2123346471 @default.
• W2076479050 cites W2126235458 @default.
• W2076479050 cites W2140111850 @default.
• W2076479050 cites W2157345824 @default.
• W2076479050 cites W2161672874 @default.
• W2076479050 cites W2162525969 @default.
• W2076479050 cites W2164452916 @default.
• W2076479050 cites W2166271687 @default.
• W2076479050 cites W2170542243 @default.
• W2076479050 cites W2327390054 @default.
• W2076479050 cites W2337039075 @default.
• W2076479050 doi "https://doi.org/10.1016/j.jchromb.2009.04.045" @default.
• W2076479050 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19505856" @default.
• W2076479050 hasPublicationYear "2009" @default.
• W2076479050 type Work @default.
• W2076479050 sameAs 2076479050 @default.
• W2076479050 citedByCount "174" @default.
• W2076479050 countsByYear W20764790502012 @default.
• W2076479050 countsByYear W20764790502013 @default.
• W2076479050 countsByYear W20764790502014 @default.
• W2076479050 countsByYear W20764790502015 @default.
• W2076479050 countsByYear W20764790502016 @default.
• W2076479050 countsByYear W20764790502017 @default.
• W2076479050 countsByYear W20764790502018 @default.
• W2076479050 countsByYear W20764790502019 @default.
• W2076479050 countsByYear W20764790502020 @default.
• W2076479050 countsByYear W20764790502021 @default.
• W2076479050 countsByYear W20764790502022 @default.
• W2076479050 countsByYear W20764790502023 @default.
• W2076479050 crossrefType "journal-article" @default.
• W2076479050 hasAuthorship W2076479050A5014858344 @default.
• W2076479050 hasAuthorship W2076479050A5017226545 @default.
• W2076479050 hasAuthorship W2076479050A5019730399 @default.
• W2076479050 hasAuthorship W2076479050A5031165822 @default.
• W2076479050 hasAuthorship W2076479050A5034931288 @default.
• W2076479050 hasAuthorship W2076479050A5039207289 @default.
• W2076479050 hasAuthorship W2076479050A5050148338 @default.
• W2076479050 hasAuthorship W2076479050A5057871927 @default.
• W2076479050 hasAuthorship W2076479050A5058631792 @default.
• W2076479050 hasAuthorship W2076479050A5089255306 @default.
• W2076479050 hasConcept C121608353 @default.
• W2076479050 hasConcept C126322002 @default.
• W2076479050 hasConcept C162356407 @default.
• W2076479050 hasConcept C185592680 @default.
• W2076479050 hasConcept C2775986502 @default.

• next